Updating results

2542 results

Sort: Relevance | Date

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID1504

In development [GID-TA10400] Expected publication date: TBC

Technology appraisal guidance In development

Transcranial magnetic stimulation for obsessive-compulsive disorder

In development [GID-IPG10134] Expected publication date: 20 May 2020

Interventional procedures guidance In development

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

In development [GID-TA10526] Expected publication date: 18 November 2020

Technology appraisal guidance In development

Barrett's oesophagus: ablative therapy

In development [GID-NG10165] Expected publication date: 17 August 2022

NICE guideline In development

Olaparib for previously treated hormone-relapsed metastatic prostate cancer [ID1640]

In development [GID-TA10584] Expected publication date: TBC

Technology appraisal guidance In development

Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Highly specialised technologies guidance In development

Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]

In development [GID-TA10381] Expected publication date: TBC

Technology appraisal guidance In development

Rezum for treating benign prostatic hyperplasia

In development [GID-MT529] Expected publication date: 06 April 2020

Medical technologies guidance In development

Atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

In development [GID-TA10590] Expected publication date: 19 May 2021

Technology appraisal guidance In development

Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

In development [GID-TA10591] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]

In development [GID-TA10571] Expected publication date: 25 August 2021

Technology appraisal guidance In development

Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

In development [GID-TA10592] Expected publication date: 23 June 2021

Technology appraisal guidance In development

Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

In development [GID-TA10593] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]

In development [GID-TA10579] Expected publication date: 21 April 0201

Technology appraisal guidance In development

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Indoor air quality at home

In development [GID-QS10113] Expected publication date: 20 October 2020

Quality standard In development

Avelumab for untreated PD-L1 positive non-small-cell lung cancer [ID1261]

In development [GID-TA10250] Expected publication date: TBC

Technology appraisal guidance In development

Elotuzumab for multiple myeloma [ID966]

In development [GID-TA10134] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis in adults: management

In development [GID-NG10153] Expected publication date: 04 May 2022

NICE guideline In development

Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer [ID1443]

In development [GID-TA10476] Expected publication date: 25 November 2020

Technology appraisal guidance In development

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]

In development [GID-TA10460] Expected publication date: 26 February 2020

Technology appraisal guidance In development

Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer [ID1140]

In development [GID-TA10181] Expected publication date: 12 February 2020

Technology appraisal guidance In development

Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547]

In development [GID-TA10459] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Technology appraisal guidance In development

Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

In development [GID-NG10098] Expected publication date: 05 November 2020

NICE guideline In development

Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: 13 January 2021

Highly specialised technologies guidance In development

The V.A.C. Veraflo Therapy system for infected wounds

In development [GID-MT543] Expected publication date: 06 October 2020

Medical technologies guidance In development

Skin tumours including Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 04 April 2022

NICE guideline In development

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: TBC

Technology appraisal guidance In development

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]

In development [GID-TA10421] Expected publication date: TBC

Technology appraisal guidance In development

Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 28 May 2021

NICE guideline In development

Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]

In development [GID-TA10529] Expected publication date: 24 June 2020

Technology appraisal guidance In development

Perioperative care in adults

In development [GID-NG10072] Expected publication date: 27 May 2020

NICE guideline In development

Mogamulizumab for treated mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma [ID1405]

In development [GID-TA10305] Expected publication date: 16 September 2020

Technology appraisal guidance In development

Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Patiromer for treating hyperkalaemia [ID877]

In development [GID-TA10273] Expected publication date: 05 February 2020

Technology appraisal guidance In development

PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: 26 August 2020

Diagnostics guidance In development

Osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302]

In development [GID-TA10255] Expected publication date: 22 January 2020

Technology appraisal guidance In development

Decision-making and mental capacity

In development [GID-QS10127] Expected publication date: 31 March 2020

Quality standard In development

Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 19 October 2021

NICE guideline In development

The MAGEC system for spinal lengthening in children with scoliosis

In development [GID-MT544] Expected publication date: 15 September 2020

Medical technologies guidance In development

Neonatal parenteral nutrition

In development [GID-QS10087] Expected publication date: 01 February 2021

Quality standard In development

Colorectal cancer (QS update)

In development [GID-QS10141] Expected publication date: 26 January 2021

Quality standard In development

Primary and secondary brain cancers

In development [GID-QS10092] Expected publication date: 26 January 2021

Quality standard In development

Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 04 April 2022

NICE guideline In development

Tobacco: preventing uptake, promoting quitting and treating dependence (update)

In development [GID-NG10086] Expected publication date: 18 January 2021

NICE guideline In development

Neonatal infection (early onset): antibiotics for prevention and treatment

In development [GID-NG10111] Expected publication date: 05 March 2021

NICE guideline In development

Perioperative care

In development [GID-QS10094] Expected publication date: 01 March 2021

Quality standard In development